Understanding how genetics influence responses to cancer immunotherapy
Discovery of host genetic elements affecting response to immune checkpoint inhibitors
['FUNDING_R01'] · JACKSON LABORATORY · NIH-11048708
This study is looking at how different genes in a person's body can affect how well cancer treatments called immune checkpoint inhibitors work, with the goal of finding out which patients might benefit the most from these therapies.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JACKSON LABORATORY (nih funded) |
| Locations | 1 site (BAR HARBOR, UNITED STATES) |
| Trial ID | NIH-11048708 on ClinicalTrials.gov |
What this research studies
This research investigates how variations in host genetics affect the response to immune checkpoint inhibitors, which are treatments used in cancer therapy. By using a unique mouse model that allows researchers to control tumor genetics while varying the host's genetic background, the study aims to identify specific genetic factors that influence treatment outcomes. The approach involves mapping genetic traits associated with responses to anti-PD1 therapy, which could help predict which patients are more likely to benefit from these treatments. This research could lead to more personalized cancer therapies based on individual genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are being considered for treatment with immune checkpoint inhibitors.
Not a fit: Patients who do not have cancer or those who are not eligible for immune checkpoint inhibitor therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for predicting patient responses to immunotherapy, enhancing treatment effectiveness.
How similar studies have performed: Previous research has shown that genetic factors can significantly influence responses to cancer treatments, suggesting that this approach has the potential for success.
Where this research is happening
BAR HARBOR, UNITED STATES
- JACKSON LABORATORY — BAR HARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIU, EDISON TAK-BUN — JACKSON LABORATORY
- Study coordinator: LIU, EDISON TAK-BUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.